Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells

BACKGROUND: Anlotinib has demonstrated encouraging clinical outcomes in the treatment of lung cancer, soft tissue sarcoma and thyroid carcinoma. Several clinical studies have shown a relationship between anlotinib treatment and the occurrence of hyperlipidemia. The fundamental mechanisms, however, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhongling, Xu, Shan, Ren, Jing, Jiang, Teng, Zhang, Cai, Yan, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464365/
https://www.ncbi.nlm.nih.gov/pubmed/37612751
http://dx.doi.org/10.1186/s12944-023-01907-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464365/
https://www.ncbi.nlm.nih.gov/pubmed/37612751
http://dx.doi.org/10.1186/s12944-023-01907-y

Ejemplares similares